AMRX Amneal Pharmaceuticals, Inc.
Stock · NasdaqGS · United States · Healthcare · US03168L1052
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Amneal Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
20.14 USD
+3.55%
52-week range
11.38 – 21.68
Dividend yield—
Market cap7.0B
NowoTrade score
36 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:27. Information, not advice.
Results
Next results
26 Feb 2027
in 110 days · 08:00 · estimate 0.24
Last results
0.26 vs 0.24 estimated
03 Nov 2026 · Beat +9.5%
Beat the estimate
11 of 12
1 missed · 0 in line · 7 beats in a row
Average surprise
+28.6%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 26 Feb 2027 08:00 | 0.24 | — | — | Upcoming |
| 03 Nov 2026 06:00 | 0.24 | 0.26 | +9.5% | Beat |
| 30 Jul 2026 06:00 | 0.23 | 0.30 | +30.3% | Beat |
| 07 May 2026 16:00 | 0.17 | 0.27 | +59.6% | Beat |
| 04 May 2026 16:00 | 0.17 | — | — | — |
| 27 Feb 2026 06:00 | 0.18 | 0.21 | +14.1% | Beat |
| 30 Oct 2025 06:00 | 0.14 | 0.17 | +22.9% | Beat |
| 05 Aug 2025 06:00 | 0.17 | 0.25 | +43.0% | Beat |
| 02 May 2025 06:00 | 0.15 | 0.21 | +43.2% | Beat |
| 28 Feb 2025 06:00 | 0.15 | 0.12 | -21.1% | Miss |
| 08 Nov 2024 06:00 | 0.14 | 0.16 | +18.3% | Beat |
| 09 Aug 2024 06:00 | 0.14 | 0.16 | +15.1% | Beat |
| 03 May 2024 06:00 | 0.09 | 0.14 | +52.1% | Beat |
| 01 Mar 2024 06:00 | 0.09 | 0.14 | +56.4% | Beat |
| 07 Nov 2023 06:00 | 0.13 | 0.19 | +49.8% | Beat |
| 04 Aug 2023 06:00 | 0.10 | 0.19 | +91.4% | Beat |
| 05 May 2023 06:00 | 0.10 | 0.12 | +25.0% | Beat |
| 02 Mar 2023 06:00 | 0.21 | 0.23 | +11.7% | Beat |
| 04 Nov 2022 06:00 | 0.18 | 0.14 | -20.6% | Miss |
| 05 Aug 2022 06:00 | 0.19 | 0.19 | -2.2% | Miss |
| 04 May 2022 06:00 | 0.13 | 0.12 | -7.6% | Miss |
| 01 Mar 2022 16:00 | 0.20 | 0.18 | -9.4% | Miss |
| 03 Nov 2021 06:00 | 0.20 | 0.21 | +2.9% | Beat |
| 09 Aug 2021 06:00 | 0.18 | 0.25 | +35.8% | Beat |
| 07 May 2021 06:00 | 0.18 | 0.20 | +13.5% | Beat |
| 26 Feb 2021 06:00 | 0.13 | 0.14 | +5.4% | Beat |
| 06 Nov 2020 06:00 | 0.12 | 0.16 | +31.6% | Beat |
| 06 Aug 2020 06:00 | 0.10 | 0.13 | +34.9% | Beat |
| 11 May 2020 06:00 | 0.09 | 0.20 | +123.2% | Beat |
| 26 Feb 2020 06:00 | 0.05 | 0.08 | +56.5% | Beat |
| 06 Nov 2019 06:00 | 0.13 | 0.04 | -68.6% | Miss |
| 05 Aug 2019 06:00 | 0.12 | 0.09 | -27.2% | Miss |
| 09 May 2019 06:00 | 0.18 | 0.14 | -20.9% | Miss |
| 28 Feb 2019 07:00 | 0.27 | 0.33 | +21.0% | Beat |
| 07 Nov 2018 16:00 | 0.27 | 0.28 | +2.3% | Beat |
| 09 Aug 2018 07:00 | 0.22 | 0.24 | +7.4% | Beat |
| 11 May 2018 07:00 | 0.10 | 0.14 | +40.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3B | +8.0% | 72.1M | 2.4% | 0.22 | +157.9% | 225.6M |
| 2024 | 2.8B | +16.7% | -116.9M | -4.2% | -0.38 | +20.8% | 220.1M |
| 2023 | 2.4B | +8.2% | -84M | -3.5% | -0.48 | +44.2% | 276.4M |
| 2022 | 2.2B | — | -130M | -5.9% | -0.86 | — | -25.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 11 Jul 2022 – 15 Jul 2022 | 3.25 | 3.36 | 3.05 | 3.13 | -5.15% | 1,897,900 | |
| 05 Jul 2022 – 08 Jul 2022 | 3.30 | 3.38 | 3.16 | 3.30 | -1.79% | 2,497,100 | |
| 27 Jun 2022 – 01 Jul 2022 | 3.24 | 3.53 | 3.12 | 3.36 | +5.00% | 2,571,900 | |
| 21 Jun 2022 – 24 Jun 2022 | 3.20 | 3.35 | 3.03 | 3.20 | +0.31% | 2,863,700 | |
| 13 Jun 2022 – 17 Jun 2022 | 3.11 | 3.48 | 2.90 | 3.19 | +0.31% | 4,689,100 | |
| 06 Jun 2022 – 10 Jun 2022 | 3.53 | 3.55 | 3.07 | 3.18 | -8.88% | 2,353,400 | |
| 31 May 2022 – 03 Jun 2022 | 3.38 | 3.77 | 3.37 | 3.49 | +0.87% | 2,877,600 | |
| 23 May 2022 – 27 May 2022 | 3.57 | 3.59 | 3.14 | 3.46 | -1.42% | 3,784,500 | |
| 16 May 2022 – 20 May 2022 | 3.39 | 3.71 | 3.37 | 3.51 | +1.74% | 2,307,400 | |
| 09 May 2022 – 13 May 2022 | 3.32 | 3.52 | 3.08 | 3.45 | +1.47% | 4,001,100 | |
| 02 May 2022 – 06 May 2022 | 3.87 | 4.08 | 3.26 | 3.40 | -11.92% | 6,471,800 | |
| 25 Apr 2022 – 29 Apr 2022 | 3.85 | 3.98 | 3.76 | 3.86 | -1.28% | 2,821,400 | |
| 18 Apr 2022 – 22 Apr 2022 | 4.10 | 4.28 | 3.89 | 3.91 | -5.10% | 3,680,200 | |
| 11 Apr 2022 – 14 Apr 2022 | 4.46 | 4.54 | 4.11 | 4.12 | -7.62% | 4,089,200 | |
| 04 Apr 2022 – 08 Apr 2022 | 4.28 | 4.60 | 4.00 | 4.46 | +3.72% | 4,192,500 | |
| 28 Mar 2022 – 01 Apr 2022 | 4.14 | 4.38 | 4.03 | 4.30 | +3.61% | 2,513,600 | |
| 21 Mar 2022 – 25 Mar 2022 | 4.19 | 4.22 | 3.98 | 4.15 | -0.95% | 4,379,200 | |
| 14 Mar 2022 – 18 Mar 2022 | 4.13 | 4.29 | 3.95 | 4.19 | +1.70% | 3,717,000 | |
| 07 Mar 2022 – 11 Mar 2022 | 4.03 | 4.25 | 3.87 | 4.12 | +1.98% | 3,418,400 | |
| 28 Feb 2022 – 04 Mar 2022 | 4.49 | 4.58 | 3.86 | 4.04 | -11.98% | 5,481,800 | |
| 22 Feb 2022 – 25 Feb 2022 | 4.62 | 4.70 | 4.28 | 4.59 | -0.86% | 1,778,300 | |
| 14 Feb 2022 – 18 Feb 2022 | 4.83 | 4.87 | 4.61 | 4.63 | -3.54% | 1,781,600 | |
| 07 Feb 2022 – 11 Feb 2022 | 4.57 | 4.98 | 4.54 | 4.80 | +4.35% | 2,399,300 | |
| 31 Jan 2022 – 04 Feb 2022 | 4.34 | 4.90 | 4.31 | 4.60 | +5.50% | 3,612,600 | |
| 24 Jan 2022 – 28 Jan 2022 | 4.41 | 4.54 | 4.17 | 4.36 | -2.24% | 2,452,900 |
Page 10 of 11
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Amneal Pharmaceuticals (AMRX) Lifts 2026 Guidance, Is The Upside Already Priced In? (opens in a new tab) Simply Wall St. · 08 Nov 2026 00:21
- Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25 (opens in a new tab) Benzinga · 05 Nov 2026 17:05
- JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25 (opens in a new tab) Benzinga · 04 Nov 2026 15:27
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised (opens in a new tab) Zacks · 04 Nov 2026 14:02
- Amneal Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 04 Nov 2026 13:45
- Should Raised 2026 Guidance Require Action From Amneal Pharmaceuticals (AMRX) Investors? (opens in a new tab) Simply Wall St. · 04 Nov 2026 13:15
- Amneal Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 04 Nov 2026 01:34
- What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 03 Nov 2026 18:14
- Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 03 Nov 2026 14:16
- Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say (opens in a new tab) Zacks · 03 Nov 2026 13:30
- Amneal Pharmaceuticals (NASDAQ:AMRX) Beats Q3 Estimates but Cash-Flow Guidance Weighs on Shares (opens in a new tab) ChartMill · 03 Nov 2026 12:21
- Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations (opens in a new tab) StockStory · 03 Nov 2026 11:30
- Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates (opens in a new tab) Zacks · 03 Nov 2026 11:25
- Amneal Reports Third Quarter 2026 Financial Results (opens in a new tab) 03 Nov 2026 11:00
- Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 03 Nov 2026 10:19
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 19.45 USD
- Market cap
- 7.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 18.2 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 14.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 4.3 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Heavy debt: net debt is 4.2× EBITDA
- Thin interest cover: operating profit is only 1.7× the interest
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 50.35× | Weak | 30.65× |
| P/E (forward) | 16.34× | Fair | 14.89× |
| Price / book | 12.73× | Weak | 3.8× |
| Price / sales | 2.2× | Fair | 3.19× |
| EV / EBITDA | 13.53× | Fair | 12.61× |
| Free cash flow yield | -0.6% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 40.1% | Good | 58.6% |
| Operating margin | 16.3% | Good | 7.6% |
| Net margin | 4.2% | Weak | 2.7% |
| Return on equity | 70% | Good | 5.7% |
| Return on assets | 7.7% | Good | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 10.9% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 5.12× | Weak | 0.48× |
| Net debt / EBITDA | 4.23× | Weak | 1.6× |
| Interest cover | 1.65× | Weak | 2.65× |
| Current ratio | 1.87× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow AMRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.